Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
Status:
Completed
Trial end date:
2018-05-26
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous
(SC) evolocumab compared with ezetimibe, on percent change from baseline in low-density
lipoprotein cholesterol (LDL-C) in hypercholesterolemic adults unable to tolerate an
effective dose of a statin.